Outcome of vagus nerve stimulation for epilepsy in Budapest.
Vagus nerve stimulation (VNS) is a nonpharmacologic therapeutic option for patients with intractable epilepsy. Better clinical outcomes were recorded in nonfocal and Lennox-Gastaut syndrome (LGS). We conducted a 2-year, open label, prospective study to measure the seizure outcome of 26 VNS patients. The seizure numbers were assessed using clinician's global impression scale (CGI) and patient diaries. The average seizure reduction was 23% at the first year and 22% at the second year. Seizure reduction was more pronounced among patients with nonfocal than with focal epilepsy. The response rate was 50% at first year and 30% at the second year. The best CGI record for clinically significant improvement was 15% in the LGS group. The only statistically significant result was the reduction of the generalized tonic-clonic seizures (GTCS). The side-effect profile was good; however, the large number of mild and reversible effects influenced the stimulation parameters and thus probably the effectiveness of the therapy. We suggest that VNS is an optional treatment mostly in cases of therapy-resistant Lennox-Gastaut syndrome. Patients with GTCS may experience improvement such as reduction of seizure severity. We conclude that VNS is a safe neuromodulatory treatment, but future developments of neuromodulatory approaches are needed.
Müller
Katalin
K
Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Fabó
Dániel
D
Entz
László
L
Kelemen
Anna
A
Halász
Péter
P
Rásonyi
György
G
Eross
Loránd
L
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004828:Epilepsies, Partial / Q000628:therapy; D004827:Epilepsy / Q000628:therapy*; D005260:Female; D006801:Humans; D006814:Hungary; D008297:Male; D055502:Secondary Prevention; D012720:Severity of Illness Index; D017211:Treatment Failure; D016896:Treatment Outcome; D055536:Vagus Nerve Stimulation / Q000379:methods; D055815:Young Adult